Childhood Craniopharyngioma - Current Strategies in Laboratory Diagnostics and Endocrine Treatment

LaboratoriumsMedizin

Volumn 27, Issue 9-10, 2003, Pages 377-385

  Muller H L ^a  

^a KLINIKUM OLDENBURG   (Germany)

Author keywords

Brain tumour; Craniopharyngioma; Hypopituitarism; Hypothalamus; Obesity; Sellar mass

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ARGININE; CHORIONIC GONADOTROPIN; CLONIDINE; CORTICOSTEROID; CORTICOTROPIN RELEASING FACTOR; DESMOPRESSIN; DEXAMETHASONE; ESTROGEN; FOLLITROPIN; GESTAGEN; GONADORELIN; HEMOGLOBIN A1C; HUMAN MENOPAUSAL GONADOTROPIN; HYDROCORTISONE; LEVOTHYROXINE; LUTEINIZING HORMONE; NORETHISTERONE; PRASTERONE SULFATE; PROLACTIN; PROTIRELIN; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE; THYROTROPIN; THYROXINE;

ADOLESCENT; ADRENAL CORTEX INSUFFICIENCY; ANTHROPOMETRIC PARAMETERS; BONE DENSITY; BRAIN EDEMA; BRAIN TUMOR; CHILD; CHILDHOOD CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CRANIOPHARYNGIOMA; DIABETES INSIPIDUS; ENDOCRINE DISEASE; GROWTH HORMONE DEFICIENCY; GYNECOMASTIA; HORMONE BLOOD LEVEL; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERADRENOCORTICISM; HYPERPROLACTINEMIA; HYPOGONADISM; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; HYPOTHALAMUS; HYPOTHYROIDISM; LABORATORY TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PROGNOSIS; PROVOCATION TEST; PUBERTY; REVIEW; SYMPTOMATOLOGY; TREATMENT INDICATION;

EID: 0242551160     PISSN: 03423026     EISSN: None     Source Type: Journal    
DOI: 10.1515/LabMed.2003.052     Document Type: Review

References (59)

1. Janzer RC, Burger PC, Giangaspero F, Paulus W. Craniopharyngioma. In: Kleihues P, Cavanee WK (eds): Pathology and genetics of tumours of the central nervous system. International Agency for Research on Cancer, 1999.
2. Einhaus SL, Sanford RA. Craniopharyngiomas. In: Albright AL, Pollack IF, Adelson PD (eds): Principles and practice of pediatric neurosurgery. New York, Thieme, 1999, pp 545-562.
3. Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM. The descriptive epidemiology of craniopharyngioma. J Neurosurg 1998;89:547-551.
4. Müller-Scholden J, Lehmbecher T, Müller HL, Bensch J, Hengen RH, Sörensen N, von Stockhausen HB. Radical surgery in a neonate with craniopharyngioma. Pediatr Neurosurg 2001;33:265-269.
5. Müller HL, Bueb K, Bartels U, Roth C, Harz K, Graf N, Korinthenberg R, Bettendorf M, Kühl J, Gutjahr P, Sörensen N, Calaminus G. Obesity after childhood craniopharyngioma - German multicenter study on pre-operative risk factors and quality of life. Klin Padiatr 2001;213:244-249.
6. Fahlbusch R, Honegger J, Paulus W, Huk W, Buchfelder M. Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg 1999;90:237-250.
7. Rajan B, Ashley S, Gorman C, Jose CC, Horwich A, Bloom HJG, Marsh H, Brada M. Craniopharyngioma - long-term results following limited surgery and radiotherapy. Radiother Oncol 1993; 26:1-10.
8. Müller HL, Kaatsch P, Warmuth-Metz M, Flentje M, Sörensen N. Childhood craniopharyngioma - current concepts in diagnostics and therapy. Monatsschr Kinderheilkd 2003, in press.
9. Roth C, Lakomek M, Müller HL, Harz KJ. Obesity in children -etiology and treatment. Monatsschr Kinderheilkd 2002;150:329-336.
10. Anand BK. Nervous regulation of food intake. Physiol Rev 1962;41:677-708.
11. De Vile CJ, Grant DB, Hayward RD, Kendall BE, Neville BG, Stanhope R. Obesity in childhood craniopharyngioma: relation to post-operative hypothalamic damage shown by magnetic resonance imaging. J Clin Endocrinol Metab 1996;81:2734-2737.
12. Müller HL, Heinrich M, Bueb K, Etavard-Gorris N, Gebhardt U, Kolb R, Sörensen N. Perioperative dexamethasone treatment in childhood craniopharyngioma - influence on short-term and long-term weight development. J Exp Clin Endocrinol Diabetes 2003, in press.
13. Müller HL, Schneider P, Bueb K, Etavard-Gorris N, Gebhardt U, Kolb R, Sörensen N. Volumetric bone mineral density in patients with childhood craniopharyngioma. J Exp Clin Endocrinol Diabetes 2003;111:168-173.
14. Müller HL, Sörensen N (eds). KRANIOPHARYGEOM 2000 -Prospective, multicenter surveillance study of children and adolescents with craniopharyngioma. Oldenburg, Universitätsverlag Aschenbeck & Isensee, 2001 (www.kraniopharyngeom.com).
15. Sklar CA. Craniopharyngioma: endocrine abnormalities at presentation. Pediatr Neurosurg 1994;21(Suppl 1):18-20.
16. Harwood-Nash DC. Neuroimaging of childhood craniopharyngioma. Pediatr Neurosurg 1994;21(Suppl):2-10.
17. Crotty TB, Scheithauer BW, Young WF, Davies DH, Shaw EG, Miller GM, Burger PC. Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg 1995;83:206-214.
18. Miller DC. Pathology of craniopharngiomas: clinical important pathological findings. Pediatr Neurosurg 1994;21(Suppl 1)11-17.
19. DeVile CJ, Grant DB, Hayward RD, Stanhope R. Growth and endocrine sequelae of craniopharyngioma. Arch Dis Child 1996;75: 108-114.
20. Honegger J, Buchfelder M, Fahlbusch R. Surgical resection of craniopharyngiomas: endocrinological results. J Neurosurg 1999;90: 251-257.
21. Yasargil MG, Curcic M, Kis M, et al. Total removal of craniopharyngiomas. Approaches and long-term results in 144 patients. J Neurosurg 1990;73:3-11.
22. Sanford RA. Craniopharyngioma: results of survey of the American Society of Pediatric Neurosurgery. Pediatr Neurosurg 1994;21 (suppl. 1):39-43.
23. Lehrnbecher T, Müller-Scholden J, Danhauser-Leistner I, Sörensen N, von Stockhausen HB. Perioperative fluid and electrolyte management in children undergoing surgery for craniopharyngioma - a 10-year experience in a single institution. Childs Nerv Syst 1998;14:276-279.
24. Price DA, Wilton P, Jönsson P, Albertson-Wikland K, Chatelain P, Cutfield W, Ranke MB. Efficacy and safety of growth hormone treatment in children with prior craniopharyngioma: an analysis of the Pharmacia and Upjohn international growth database (KIGS) from 1988 to 1996. Horm Res 1998;49:91-97.
25. Hogeveen M, Noordam C, Wit JM, Massa G. Growth before and during growth hormone treatment in children operated for craniopharyngioma. Horm Res 1997;48:258-262.
26. Bucher H, Zapf J, Torresani T, Prader A, Froesch ER, Illig R. Insulin-like growth factors I and II, prolactin, and insulin in 19 growth hormone deficient children with excessive, normal or decreased longitudinal growth after operation for craniopharyngioma. N Engl J Med 1983;309:1142-1146.
27. Finkelstein JW, Kream J, Ludan A, Hellman L. Sulfation factor (somatomedin): an explanation for continued growth in the absence of immunoassayable growth hormone in patients with hypothalamic tumors. J Clin Endocrinol Metab 1972;35:13-17.
28. Geffner ME. The growth without growth hormone syndrome. Endocrinol Metab Clin North Am 1996;25:649-663.
29. Flynn FG, Cummings JL, Tomiyasu U. Altered behavior associated with damage to the ventromedial hypothalamus: a distinctive syndrome. Behav Neurol 1988;1:49-58.
30. Albert DJ, Petrovic DM, Jonik RH, Walsh ML. Enhanced defensiveness and increased food motivation each contribute to aggression and success in food competition by rats with medial hypothalamic lesions. Physiol Behav 1991;49:13-19.
31. Eclancher F, Karli P. Interspecific aggressive and feeding behavior: effects of lesions of the ventromedial hypothalamic nucleus. Brain Res 1971;26:71-79.
32. Blundell JE. Neuroregulators and feeding: implications for the pharmacological manipulation of hunger and appetite. Rev Pure Appl Pharmacol Sci 1982;3:381-462.
33. Blundell JE. Appetite disturbance and the problems of overweight. Drugs 1990;39:1-19.
34. Stellar E. The physiology of motivation. Psychol Rev 1954;61: 5-22.
35. Stricker EM. Hyperphagia. N Engl J Med 1978;298:5-22.
36. Gold RM. Hypothalamic obesity: the myth of the ventromedial nucleus. Science 1973;182:488-490.
37. Ahlskog JE, Randall PK, Hoebel BG. Hypothalamic hyperphagia: dissociation from hyperphagia following destruction of noradrenergic neuroma. Science 1975;190:399-401.
38. Leibowitz SF, Weiss GF, Shor-Posner G. Medial hypothalamic serotonin in the control of eating behavior. Int J Obes 1987;11: 110-123.
39. Leibowitz SF, Weiss GF, Shor-Posner G. Hypothalamic serotonin: pharmacological, biochemical and behaviour analyses of its feeding-suppressive action. Clin Neuropharmacol 1988;11:51-71.
40. Leibowitz SF. The role of serotonin in eating disorder. Drugs 1990;39:33-48.
41. Jordaan GP, Roberts MC, Emsley RA. Serotonergic agents in the treatment of hypothalamic obesity syndrome: a case report. Int J Eat Disord 1996;20:111-113.
42. Roth C, Wilken B, Hanefeld F, Schröter W, Leonhardt U. Hyperphagia in children with craniopharyngioma is associated with hyperleptinemia and a failure in the downregulation of appetite. Eur J Endocrinol 1998;138:89-91.
43. Brabant G, Horn R, Mayr B, von zur Mühlen A, Honegger J, Buchfelder M. Serum leptin levels following hypothalamic surgery. Horm Metab Res 1996;28:728-731.
44. Sippell WG, Mönig H, Partsch CJ. Endokrinologische Funktionsdiagnostik. Kiel, Schmidt & Klaunig, 1999.
45. Hindmarsh PC, Swift PGF. An assessment of growth hormone provocation tests. Arch Dis Child 1995;72:362-367.
46. Tassoni P, Cacciari E, Cau M, Colli C, Tosi M, Zucchini S, Cicognani A, Pirazzoli P, Salardi S, Balsamo A, Frejaville E, Cassio A, Zappulla F. Variability of growth hormone response to pharmacological and sleep tests performed twice in short children. J Clin Endocrinol Metab 1990;71:230-234.
47. Zadik Z, Chalew SA, Gilula Z, Kowarski AA. Reproducibility of growth hormone testing procedures. A comparison between 24-hour integrated concentration and pharmacological stimulation. J Clin Endocrinol Metab 1990;71:1127-1130.
48. Berendes E, Walter M, Cullen P, Prien T, Van Aken H, Horsthemke J, Schulte M, von Wild K, Scherer R. Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet 1997;349:245-249.
49. Ganong CA, Kappy MS. Cerebral salt wasting in children. The need for recognition and treatment. Am J Dis Child 1993;147:167-169.
50. Laredo S, Yuen K, Sonnenberg B, Halperin ML. Coexistence of central diabetes insipidus and salt wasting: the difficulties in diagnosis, changes in natremia, and treatment. J Am Soc Nephrol 1996;7: 2527-2532.
51. Sakarcan A, Bocchini J. The role of fludrocortisone in a child with cerebral salt wasting. Pediatr Nephrol 1998;12:769-771.
52. Holl R. Hypophysäre Störungen. In: Kruse K (Hrsg.): Pädiatrische Endokrinologie. Stuttgart, Enke Verlag, 1999, pp 1-29.
53. Hetelekidis S, Barnes PD, Tao ML, Fischer EG, Schneider L, Scott RM, Tarbell NJ. 20-year experience in childhood craniopharyngioma. Int J Radiat Oncol Biol Phys 1993;27:189-195.
54. Harz K, Müller HL, Waldeck E, Pudel V, Roth C. Obesity in patients with cranio-pharyngioma: assessment of physical activity and food intake. J Clin Endocrinol Metab 2003, in press.
55. Müller HL, Handwerker G, Wollny B, Sörensen N. Melatonin secretion and increased daytime sleepiness in childhood craniopharyngioma patients. J Clin Endocrinol Metab 2002;87:3993-3996.
56. Lustig RH, Post SM, Srivannaboom K, Rose SR, Danish RK, Burghen GA, Wu S, Xiong X, Merchant TE. Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab 2003;88:611-616.
57. Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, Schreiber RE, Rai SN, Lensing SY, Wu S. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2003;88:2586-2592.
58. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. Stanford, Stanford University Press, 1959.
59. Rolland-Cachera MF, Cole TJ, Sempé, Tichet J, Rossignol C, Charraud A. Body mass index variations: centiles from birth to 87 years. Eur J Clin Nutrition 1991;45:13-21.